NEW ORLEANS, La. — At the American Academy of Optometry’s 2023 Annual Meeting, SightGlass Vision shared three studies that further emphasized the efficacy of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. Individually and collectively, they reinforce the robust performance of the company’s flagship myopia control intervention, which uses thousands of light-scattering elements called dots to mimic more natural contrast on the retina — a unique mechanism of action to slow myopia progression in children.
In-depth data from “Control of Myopia Using Diffusion Optics Technology Spectacle Lenses: 4-Year Results (CYPRESS)” was presented by Dr. Debbie Laughton, demonstrating statistically significant slowing of axial length (AL) progression and cycloplegic spherical equivalent refraction (cSER). Expanding on top line findings shared last month from the rigorous, multi-site study, researchers report that children wearing their DOT 0.2 spectacles full-time continue to show substantial clinical benefit over 48 months.
Among the additional data reported at Academy ’23 is visual performance among CYPRESS participants over the four-year span. Mean binocular high contrast LogMAR visual acuity (VA) measurements were clinically stable and similar between groups at distance (test -0.09 ± 0.08, control -0.07 ± 0.06) and near (test -0.03 ± 0.14, control -0.04 ± 0.10). Mean monocular low contrast (10%) distance VA showed an improvement over the course of the study (mean change from baseline: test 0.05 ± 0.12, control 0.07 ± 0.11), and mean peripheral VA improved or remained similar in all quadrants, with no significant differences between treatment groups.
The CYPRESS paper was selected by the Academy as one of the six most newsworthy presentations in New Orleans. Dr. Laughton summarized the work during the Academy-hosted Innovations in Vision and Eye Care event.
A companion study co-developed by researcher and Professor James Wolffsohn of Aston University assessed the “Visual Impact of Diffusion Optics Technology Lenses for Myopia Control.” Children (12.2±1.3 years old, range 10-14, 51% female) were randomly assigned to wear DOT 0.2 spectacle lenses (n=27) or single vision lenses (n=24) for 3.5 years across six North American sites. Investigators determined that the DOT 0.2 lens provides an equivalent visual experience to a standard single vision lens, as evaluated through binocular high and low contrast distance visual acuities, near visual acuity, reading speed, contrast sensitivity, stereoacuity and glare measures.
Presented by Dr. Kylvin Ho of C U Vision Optometrists (Vancouver), “Real-World Effectiveness of Diffusion Optics Technology (DOT) Spectacle Lenses for Myopia Control in Chinese Canadian Children” identified 39 patients who were prescribed the intervention as a monotherapy between October 2020 to December 2022 in an independent practice. After 12 months, mean progression was -0.28 ± 0.32D in SER (n=39) and 0.15 ± 0.17 mm in AL (n=36). SER progression was limited to -0.25D or less in 56% of children during the time frame.
Compared to Singapore Cohort Study of the Risk Factors for Myopia (SCORM) data, DOT 0.2 lenses slowed AL progression by 62% (0.24 mm). The 12-month AL elongation was similar to 0.14 mm SCORM-predicted, age-matched emmetropic eye growth (physiological eye growth). The Canadian practice data also aligned with CYPRESS study 12-month outcomes of 0.15 mm AL progression.
“Myopia progression is one of the greatest health epidemics of our time, deserving of attention and resources from researchers, educators, and policy makers. The evidence-based efficacy and impact of Diffusion Optics Technology spectacle lenses, clearly and convincingly demonstrated across multiple dimensions at Academy ’23, shows their substantial potential to change the lives of children around the world. We thank the Academy for recognizing CYPRESS as among the most compelling and robust science to be presented this year, and we look forward to sharing more with colleagues over the coming days,” said Andrew Sedgwick, CEO of SightGlass Vision.
Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy1-3 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.
* SightGlass Vision Diffusion Optics Technology spectacle lenses are not available for sale in the United States.
1 Rappon J., et al. Control of myopia using Diffusion Optics Technology spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005
2 Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.
3 Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.